We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population.
1. What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor inhibitors? (0:05)
2. Could you tell us a little about the aims and design of the KEYNOTE-641 study? (0:50)
3. What are the eligibility criteria for this study? (1:23)
4. How can we overcome the challenge of identifying biomarkers predictive of response to pembrolizumab? (1:55)
5. What other combined therapeutic approaches involving androgen receptor inhibitors are being investigated in the treatment of mCRPC? (2:51)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Julie Graff has received travel expenses from Sanofi.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Prostate Cancer
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!